PVP Ventures Limited submitted an updated Annual Report for FY2025-26 to the stock exchanges on October 6, 2026, incorporating two post-submission modifications to the original report filed on August 14, 2026.

Nature of the Updates

The updated report includes two distinct changes, both of which are enclosed alongside the original Annual Report:

The company confirmed that apart from these changes, there is no change in the financial statements and other material information contained in the Annual Report already submitted to the stock exchanges.

Addendum: Compliance Certificate for Name Change

The addendum, dated August 20, 2026, pertains to a compliance certificate issued by a practising chartered accountant under Regulation 45(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The certificate relates to Item No. 5 of the AGM Notice concerning the proposed change of the company's name from PVP Ventures Limited to Evervie Health Limited.

The certificate, issued by M/s CNGSN & Associates LLP, Chartered Accountants, certifies compliance with Regulation 45(1) of the SEBI LODR Regulations. Key findings from the certificate include:

• A period of at least one year has elapsed since the last change of name of the company, satisfying Regulation 45(1)(a).
• The amount invested by the company in the new healthcare activity is ₹179.40 crore, representing 77% of the company's assets as defined under the Explanation to Regulation 45, thereby satisfying the minimum 50% threshold under Regulation 45(1)(c).

The assets of the company for the purpose of Regulation 45, based on the audited financial statements as on March 31, 2026, are summarised below:

Corrigendum: Revision to AGM Agenda Item No. 10

The corrigendum, dated August 29, 2026, amends the title and resolution text of Item No. 10 in the Notice of the 35th Annual General Meeting. The original item was titled "Approval of Payment of Managerial Remuneration to Mr. Prasad V. Potluri, Chairman and Managing Director and Payment of Fees Towards Collateral Securities and Personal Guarantees Provided by Him."

The revised title reads: "Re-appointment and Approval of Payment of Managerial Remuneration to Mr. Prasad V. Potluri, Chairman and Managing Director and Payment of Fees Towards Collateral Securities and Personal Guarantees Provided by Him."

The revised resolution now additionally seeks member approval for the re-appointment of Prasad V. Potluri as Chairman and Managing Director for a period of five years commencing from the conclusion of the 35th AGM until the conclusion of the Annual General Meeting to be held in the year 2031. The proposed managerial remuneration of ₹5,00,00,000 (Rupees Five Crores only) for FY2026-27, and the fee structure of 2% per annum on collateral securities and 1% per annum on personal guarantees, remain unchanged from the original notice.

All other contents of the AGM Notice and the Annual Report for FY2025-26 remain unchanged.

Financial Highlights from the Annual Report

The Annual Report for FY2025-26 discloses the following summarised financial results (₹ in Lakhs):

On a standalone basis, the company reported a profit after tax of ₹72.32 lakhs for FY2025-26 compared to a loss of ₹390.40 lakhs in FY2024-25. Standalone revenue from operations stood at ₹3,292.29 lakhs against ₹1,690.24 lakhs in the previous year.

During the year, the company completed the acquisition of majority stakes in Biohygea Global Private Limited, Optimus Oncology Private Limited, and 7Med India Private Limited. The company also issued Non-Convertible Debentures aggregating ₹150 crores on a private placement basis, comprising 9,500 Series A debentures and 5,500 Series B debentures, each of face value ₹1,00,000.

PVP Ventures Ltd confirmed the payment of interest on its Non-Convertible Debentures (NCDs) on October 3, 2026. The payout, totaling ₹1.04 crore, was made three days after the scheduled due date of September 30, 2026.

The company attributed the delay to a "technical issue" in its intimation to stock exchanges. The payment covers two separate debt instruments with an aggregate issue size of ₹150 crore. The record date for this interest cycle was September 23, 2026.

Payment details and instrument specifics

The interest was disbursed to debenture holders listed as beneficial owners on the record date. The total amount paid comprises ₹65.68 lakh for one series and ₹38.02 lakh for another. Both instruments carry a quarterly interest frequency.

Regulatory compliance and context

This disclosure was made under Regulation 57 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that no change in the frequency of interest payments occurred during this period. The previous interest payment was made on July 21, 2026.

What the numbers show

The combined interest outflow of ₹1.04 crore against a total principal exposure of ₹150 crore implies an annualized yield of approximately 2.77% if viewed in isolation, though quarterly compounding or specific coupon structures may vary. The consistent quarterly payment schedule indicates regular debt servicing obligations, with the current delay being attributed to operational rather than liquidity constraints.